ABSTRACT
Hepatitis delta virus (HDV) is the only animal RNA virus that has an unbranched rod-like genome with ribozyme activity and is replicated by host RNA polymerase. HDV RNA recombination was previously demonstrated in patients and in cultured cells by analysis of a region corresponding to the C terminus of the delta antigen (HDAg), the only viral-encoded protein. Here, a whole-genome recombination map of HDV was constructed using an experimental system in which two HDV-1 sequences were co-transfected into cultured cells and the recombinants were analysed by sequencing of cloned reverse transcription-PCR products. Fifty homologous recombinants with 60 crossovers mapping to 22 junctions were identified from 200 analysed clones. Small HDAg chimeras harbouring a junction newly detected in the recombination map were then constructed. The results further indicated that the genome-replication level of HDV was sensitive to the sixth amino acid within the N-terminal 22 aa of HDAg. Therefore, the recombination map established in this study provided a tool for not only understanding HDV RNA recombination, but also elucidating the related mechanisms, such as molecular elements responsible for the trans-activation levels of the small HDAg.
Subject(s)
Antigens, Viral/genetics , Genome, Viral , Hepatitis Delta Virus/genetics , RNA, Viral/genetics , Recombination, Genetic , Animals , COS Cells , Chlorocebus aethiops , Cloning, Molecular , Genome-Wide Association Study , Genotype , Hepatitis Delta Virus/immunology , Models, Genetic , Phylogeny , Transcriptional Activation , Virus ReplicationABSTRACT
We describe the discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel agonists of GPR119. Previously described aniline 2 had suboptimal efficacy in signaling assays using cynomolgus monkey (cyno) GPR119 making evaluation of the target in preclinical models difficult. Replacement of the aniline ring with a tetrahydroquinoline ring constrained the rotation of the aniline C-N bond and gave compounds with increased efficacy on human and cyno receptors. Additional optimization led to the discovery of 10, which possesses higher free fraction in plasma and improved pharmacokinetic properties in rat and cyno compared to 2.
Subject(s)
Drug Discovery , Oxadiazoles/pharmacology , Quinolines/pharmacology , Receptors, G-Protein-Coupled/agonists , Animals , Dose-Response Relationship, Drug , Humans , Macaca fascicularis , Molecular Structure , Oxadiazoles/chemical synthesis , Oxadiazoles/chemistry , Quinolines/chemical synthesis , Quinolines/chemistry , Rats , Structure-Activity RelationshipABSTRACT
The discovery and optimization of novel N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamide GPR119 agonists is described. Modification of the pyridylphthalimide motif of the molecule with R(1)=-Me and R(2)=-(i)Pr substituents, incorporated with a 6-fluoro substitution on the central phenyl ring offered a potent and metabolically stable tool compound 22.
Subject(s)
Drug Discovery , Pyridines/pharmacology , Receptors, G-Protein-Coupled/agonists , Sulfonamides/pharmacology , Animals , Dose-Response Relationship, Drug , Humans , Microsomes, Liver/chemistry , Microsomes, Liver/metabolism , Molecular Structure , Pyridines/chemistry , Pyridines/metabolism , Rats , Structure-Activity Relationship , Sulfonamides/chemistry , Sulfonamides/metabolismABSTRACT
Hepatitis delta virus (HDV), an RNA virus with two forms of the delta antigen (HDAg), relies on hepatitis B virus (HBV) for envelope proteins essential for hepatocyte entry. Hepatocellular carcinoma (HCC) ranks third in global cancer deaths, yet HDV's involvement remains uncertain. Among 300 HBV-associated HCC serum samples from Taiwan's National Health Research Institutes, 2.7% (8/300) tested anti-HDV positive, with 62.7% (5/8) of these also HDV RNA positive. Genotyping revealed HDV-2 in one sample, HDV-4 in two, and two samples showed mixed HDV-2/HDV-4 infection with RNA recombination. A mixed-genotype infection revealed novel mutations at the polyadenylation signal, coinciding with the ochre termination codon for the L-HDAg. To delve deeper into the possible oncogenic properties of HDV-2, the predominant genotype in Taiwan, which was previously thought to be less associated with severe disease outcomes, an HDV-2 cDNA clone was isolated from HCC for study. It demonstrated a replication level reaching up to 74% of that observed for a widely used HDV-1 strain in transfected cultured cells. Surprisingly, both forms of HDV-2 HDAg promoted cell migration and invasion, affecting the rearrangement of actin cytoskeleton and the expression of epithelial-mesenchymal transition markers. In summary, this study underscores the prevalence of HDV-2, HDV-4, and their mixed infections in HCC, highlighting the genetic diversity in HCC as well as the potential role of both forms of the HDAg in HCC oncogenesis.
Subject(s)
Carcinoma, Hepatocellular , Genetic Variation , Genotype , Hepatitis Delta Virus , Liver Neoplasms , Carcinoma, Hepatocellular/virology , Hepatitis Delta Virus/genetics , Humans , Liver Neoplasms/virology , Male , Middle Aged , Carcinogenesis/genetics , Female , Taiwan , Evolution, Molecular , Virus Replication , Phylogeny , RNA, Viral/genetics , Hepatitis D/virology , Aged , Hepatitis B virus/geneticsABSTRACT
We describe the discovery of a series of arylsulfonyl 3-(pyridin-2-yloxy)anilines as GPR119 agonists derived from compound 1. Replacement of the three methyl groups in 1 with metabolically stable moieties led to the identification of compound 34, a potent and efficacious GPR119 agonist with improved pharmacokinetic (PK) properties.
Subject(s)
Aniline Compounds/chemistry , Aniline Compounds/pharmacology , Receptors, G-Protein-Coupled/agonists , Aniline Compounds/chemical synthesis , Animals , Diabetes Mellitus, Type 2/drug therapy , Drug Discovery , Humans , Mice , Models, Molecular , Receptors, G-Protein-Coupled/chemistry , Structure-Activity RelationshipABSTRACT
KEY MESSAGE: The altered ultrastructure and composition of cuticular wax from 'glossy Newhall' (MT) fruits lead to its glossy phenotype. A novel mutant derived from the wild-type (WT) 'Newhall' navel orange (Citrus sinensis [L.] Osbeck cv. Newhall), named 'glossy Newhall' (MT), which produced much more glossy fruits that were easily distinguishable from the WT fruits was characterized in this report. The total wax loads of both WT and MT fruits varied considerably during the fruit development. The most abundant wax fraction of WT mature fruits was triterpenoids, followed by aldehydes, alkanes, fatty acids, primary alcohol and cholesterol. The total wax load in MT mature fruits was reduced by 44.2 % compared with WT. Except for the minor wax components of primary alcohol and cholesterol, the amounts of all major wax fractions in MT mature fruits were decreased in varying degrees. The major reduction occurred in aldehydes that decreased 96.4 % and alkanes that decreased 81.9 %, which was consistent with scanning electron micrographs of MT mature fruit surfaces that showed a severe loss of wax crystals. Hence, aldehydes and alkanes were suggested to be required for wax crystal formation in 'Newhall' navel orange fruits.
Subject(s)
Citrus sinensis/chemistry , Fruit/chemistry , Fruit/ultrastructure , Waxes/chemistry , Aldehydes/chemistry , Alkanes/chemistry , Cholesterol/chemistry , Citrus sinensis/anatomy & histology , Citrus sinensis/genetics , Citrus sinensis/growth & development , Fatty Acids/chemistry , Fruit/growth & development , Microscopy, Electron, Scanning , Phenotype , Species Specificity , Triterpenes/chemistryABSTRACT
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum LDL cholesterol (LDL-C) by interacting with the LDL receptor (LDLR) and is an attractive therapeutic target for LDL-C lowering. We have generated a neutralizing anti-PCSK9 antibody, mAb1, that binds to an epitope on PCSK9 adjacent to the region required for LDLR interaction. In vitro, mAb1 inhibits PCSK9 binding to the LDLR and attenuates PCSK9-mediated reduction in LDLR protein levels, thereby increasing LDL uptake. A combination of mAb1 with a statin increases LDLR levels in HepG2 cells more than either treatment alone. In wild-type mice, mAb1 increases hepatic LDLR protein levels approximately 2-fold and lowers total serum cholesterol by up to 36%: this effect is not observed in LDLR(-/-) mice. In cynomolgus monkeys, a single injection of mAb1 reduces serum LDL-C by 80%, and a significant decrease is maintained for 10 days. We conclude that anti-PCSK9 antibodies may be effective therapeutics for treating hypercholesterolemia.
Subject(s)
Antibodies, Monoclonal/immunology , Cholesterol/blood , Neutralization Tests , Serine Endopeptidases/immunology , Animals , Cholesterol/immunology , Crystallography, X-Ray , Macaca fascicularis , Mice , Mice, Inbred C57BL , Mice, Knockout , Proprotein Convertase 9 , Proprotein Convertases , Receptors, LDL/genetics , Receptors, LDL/physiologyABSTRACT
Previous efforts have led to the identification of a potent, selective, and nonphlorizin based SGLT2 inhibitor 1. This Letter describes efforts to further optimize the potency, microsomal stability, solubility and pharmacokinetic properties of this series of SGLT2 inhibitors. From these efforts, compounds 28 and 32 have improved solubility and pharmacokinetic properties compared to compound 1.
Subject(s)
Triazoles/chemical synthesis , Drug Stability , Molecular Structure , Phlorhizin/chemistry , Solubility , Structure-Activity Relationship , Triazoles/chemistryABSTRACT
A new structural class of DGAT1 inhibitors was discovered and the structure-activity relationship was explored. The pyrrolotriazine core of the original lead molecule was changed to a pyrrolopyridazine core providing an increase in potency. Further exploration resulted in optimization of the propyl group at C7 and the discovery that the ester at C6 could be replaced by five-membered heterocyclic rings. The analogs prepared have DGAT1 IC(50) values ranging from >10 µM to 48 nM.
Subject(s)
Diacylglycerol O-Acyltransferase/antagonists & inhibitors , Diacylglycerol O-Acyltransferase/metabolism , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Pyridazines/chemistry , Pyridazines/pharmacology , Pyrroles/chemistry , Pyrroles/pharmacology , Cell Line , Enzyme Inhibitors/chemical synthesis , Humans , Inhibitory Concentration 50 , Pyridazines/chemical synthesis , Pyrroles/chemical synthesis , Sterol O-Acyltransferase/antagonists & inhibitors , Sterol O-Acyltransferase/metabolism , Structure-Activity RelationshipABSTRACT
The in vivo role of the nuclear receptor SHP in feedback regulation of bile acid synthesis was examined. Loss of SHP in mice caused abnormal accumulation and increased synthesis of bile acids due to derepression of rate-limiting CYP7A1 and CYP8B1 hydroxylase enzymes in the biosynthetic pathway. Dietary bile acids induced liver damage and restored feedback regulation. A synthetic agonist of the nuclear receptor FXR was not hepatotoxic and had no regulatory effects. Reduction of the bile acid pool with cholestyramine enhanced CYP7A1 and CYP8B1 expression. We conclude that input from three negative regulatory pathways controls bile acid synthesis. One is mediated by SHP, and two are SHP independent and invoked by liver damage and changes in bile acid pool size.
Subject(s)
Bile Acids and Salts/biosynthesis , Gene Expression Regulation , Receptors, Cytoplasmic and Nuclear/physiology , Animals , Cholesterol/metabolism , Cholesterol 7-alpha-Hydroxylase/blood , Cholestyramine Resin/administration & dosage , Cholestyramine Resin/pharmacology , DNA-Binding Proteins/metabolism , Feedback , Isoxazoles/pharmacology , Liver X Receptors , Male , Mice , Mice, Knockout , Microsomes, Liver/enzymology , Nuclear Proteins/metabolism , Orphan Nuclear Receptors , RNA-Binding Proteins/metabolism , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Cytoplasmic and Nuclear/metabolism , Steroid Hydroxylases/blood , Transcription Factors/metabolism , Triglycerides/blood , mRNA Cleavage and Polyadenylation FactorsABSTRACT
Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.
Subject(s)
Cholesterol, LDL/blood , Serine Endopeptidases/chemistry , Serine Endopeptidases/physiology , Cholesterol, LDL/antagonists & inhibitors , Crystallography, X-Ray , Humans , Peptide Fragments/chemistry , Peptide Fragments/physiology , Proprotein Convertase 9 , Proprotein Convertases , Protein Folding , Protein Interaction MappingABSTRACT
Hepatitis delta virus (HDV) RNA forms an unbranched rod-like structure and complexes with the delta antigen (HDAg). Host ADAR1-catalyzed RNA editing at the amber/W site of the small HDAg leads to the production of the large HDAg, which inhibits replication and is required for virion assembly. For HDV genotype 1, amber/W editing is controlled by HDAg and the RNA structure immediate vicinity and downstream of the editing site. Here, the effects of 20 mutants carrying an increased length of consecutive base-pairing at various sites in HDV RNA on amber/W site editing were examined. All nine mutants carrying genomic regions that formed up to 15 consecutive base pairs, which is also the maximum length observed in 41 naturally occurring HDV genomes, showed normal editing rate. However, mutants carrying a 16 or 17 consecutive base-paired antigenomic segment located as far as 114 nt upstream could increase editing efficiency, possibly by interfering with HDAg binding. These data show for the first time that extended base-pairing upstream of the amber/W site could increase HDV RNA editing efficiency. Furthermore, it appears that the naturally occurring HDV RNA structures have been selected for suboptimal amber/W RNA editing, which favors the HDV replication cycle.
Subject(s)
Adenosine Deaminase , Hepatitis Delta Virus/genetics , Hepatitis delta Antigens , RNA Editing , RNA-Binding Proteins , Adenosine Deaminase/chemistry , Adenosine Deaminase/metabolism , Cell Line , Hepatitis delta Antigens/chemistry , Hepatitis delta Antigens/metabolism , Humans , RNA, Viral/genetics , RNA-Binding Proteins/chemistry , RNA-Binding Proteins/metabolism , Structure-Activity RelationshipABSTRACT
11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) catalyzes the NADPH dependent interconversion of inactive cortisone to active cortisol. Excess 11beta-HSD1 or cortisol leads to insulin resistance and metabolic syndrome in animal models and in humans. Inhibiting 11beta-HSD1 activity signifies a promising therapeutic strategy in the treatment of Type 2 diabetes and related diseases. Herein, we report two highly potent and selective small molecule inhibitors of human 11beta-HSD1. While compound 1, a sulfonamide, functions as a simple substrate competitive inhibitor, compound 2, a triazole, shows the kinetic profile of a mixed inhibitor. Co-crystal structures reveal that both compounds occupy the 11beta-HSD1 catalytic site, but present distinct molecular interactions with the protein. Strikingly, compound 2 interacts much closer to the cofactor NADP+ and likely modifies its binding. Together, the structural and kinetic analyses demonstrate two distinctive molecular inhibition mechanisms, providing valuable information for future inhibitor design.
Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 1/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Metabolic Diseases/pathology , 11-beta-Hydroxysteroid Dehydrogenase Type 1/chemistry , Amino Acid Sequence , Binding Sites , Biological Assay , Catalysis , Crystallography, X-Ray , Enzyme Inhibitors/chemistry , Humans , Kinetics , Metabolic Diseases/enzymology , Molecular Sequence Data , NADP/metabolism , Structure-Activity Relationship , Sulfonamides/chemistry , Sulfonamides/pharmacology , Triazoles/chemistry , Triazoles/pharmacologyABSTRACT
The start-up of the anaerobic ammonium oxidation (anammox) process in three up-flow column reactors seeded with common mixed activated sludge and added with three materials, sponge (R1), sponge + volcanic rock (R2) and sponge + charcoal (R3), as carriers for biofilm formation were comparatively investigated in this study. The supplement of volcanic rock and charcoal could significantly shorten the start-up time of the anammox process, which primarily occurred in the activity-enhanced phase, with ammonium and nitrite removal efficiencies stabilized above 92.5% and 93.4% after an operation period of 145, 105 and 121 d for R1, R2 and R3, respectively. After the successful anammox start-up, R2 performed significantly better in TN removal (p < .05), achieving an average rate of 91.0% and 191.5â gâ Nâ m-3â d-1 compared to R1 of 88.4% and 172.1â gâ Nâ m-3â d-1, and R3 of 89.9% and 180.1â gâ Nâ m-3â d-1 in the steady running phase. The ratios of consumed [Formula: see text] and generated [Formula: see text]/consumed [Formula: see text] after anammox start-up were lower than the theoretical values, probably suggesting the simultaneous existences of anammox, denitrification as well as nitrification processes in the reactors. A reddish brown biofilm was wrapped on the carriers and morphological detection of biofilm displayed the presentations of thick and compact floc aggregates and some filamentous bacteria on the sponge, and spherical-, ovoid- and shortrod-shaped microorganisms on the volcanic rock and charcoal. Using porous material as carrier for biofilm development is an effective strategy for practical application of the anammox reactor.
Subject(s)
Biofilms/growth & development , Nitrogen/metabolism , Waste Disposal, Fluid/methods , Water Pollutants, Chemical/analysis , Ammonium Compounds , Bioreactors/microbiology , Charcoal , Chemoautotrophic Growth , Denitrification , Nitrification , Nitrites , Nitrogen/analysis , Oxidation-Reduction , Sewage/microbiology , Water Pollutants, Chemical/metabolismABSTRACT
The genome of hepatitis delta virus (HDV) is a 1.7-kb single-stranded circular RNA that folds into an unbranched rod-like structure and has ribozyme activity. HDV redirects host RNA polymerase(s) (RNAP) to perform viral RNA-directed RNA transcription. RNA recombination is known to contribute to the genetic heterogeneity of HDV, but its molecular mechanism is poorly understood. Here, we established a whole-genome HDV-1/HDV-4 recombination map using two cloned sequences coexisting in cultured cells. Our functional analyses of the resulting chimeric delta antigens (the only viral-encoded protein) and recombinant genomes provide insights into how recombination promotes the genotypic and phenotypic diversity of HDV. Our examination of crossover distribution and subsequent mutagenesis analyses demonstrated that ribozyme activity on HDV genome, which is required for viral replication, also contributes to the generation of an inter-clade junction. These data provide circumstantial evidence supporting our contention that HDV RNA recombination occurs via a replication-dependent mechanism. Furthermore, we identify an intrinsic asymmetric bulge on the HDV genome, which appears to promote recombination events in the vicinity. We therefore propose a mammalian RNAP-driven and viral-RNA-structure-promoted template-switching mechanism for HDV genetic recombination. The present findings improve our understanding of the capacities of the host RNAP beyond typical DNA-directed transcription.
ABSTRACT
Growth/differentiation factor 15 (GDF15), also known as MIC-1, is a distant member of the transforming growth factor-ß (TGF-ß) superfamily and has been implicated in various biological functions, including cancer cachexia, renal and heart failure, atherosclerosis and metabolism. A connection between GDF15 and body-weight regulation was initially suggested on the basis of an observation that increasing GDF15 levels in serum correlated with weight loss in individuals with advanced prostate cancer. In animal models, overexpression of GDF15 leads to a lean phenotype, hypophagia and other improvements in metabolic parameters, suggesting that recombinant GDF15 protein could potentially be used in the treatment of obesity and type 2 diabetes. However, the signaling and mechanism of action of GDF15 are poorly understood owing to the absence of a clearly identified cognate receptor. Here we report that GDNF-family receptor α-like (GFRAL), an orphan member of the GFR-α family, is a high-affinity receptor for GDF15. GFRAL binds to GDF15 in vitro and is required for the metabolic actions of GDF15 with respect to body weight and food intake in vivo in mice. Gfral-/- mice were refractory to the effects of recombinant human GDF15 on body-weight, food-intake and glucose parameters. Blocking the interaction between GDF15 and GFRAL with a monoclonal antibody prevented the metabolic effects of GDF15 in rats. Gfral mRNA is highly expressed in the area postrema of mouse, rat and monkey, in accordance with previous reports implicating this region of the brain in the metabolic actions of GDF15 (refs. 4,5,6). Together, our data demonstrate that GFRAL is a receptor for GDF15 that mediates the metabolic effects of GDF15.
Subject(s)
Area Postrema/metabolism , Eating/drug effects , Glial Cell Line-Derived Neurotrophic Factor Receptors/genetics , Growth Differentiation Factor 15/pharmacology , Obesity/metabolism , Weight Loss/drug effects , Animals , Brain/metabolism , Eating/genetics , Flow Cytometry , Glial Cell Line-Derived Neurotrophic Factor Receptors/metabolism , HEK293 Cells , Humans , Immunoblotting , Macaca fascicularis , Male , Mice , Mice, Knockout , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Real-Time Polymerase Chain Reaction , Surface Plasmon Resonance , Weight Loss/geneticsABSTRACT
Hepatitis delta virus (HDV) replication is carried out by host RNA polymerases. Since homologous inter-genotypic RNA recombination is known to occur in HDV, possibly via a replication-dependent process, we hypothesized that the degree of sequence homology and the replication level should be related to the recombination frequency in cells co-expressing two HDV sequences. To confirm this, we separately co-transfected cells with three different pairs of HDV genomic RNAs and analyzed the obtained recombinants by RT-PCR followed by restriction fragment length polymorphism and sequencing analyses. The sequence divergence between the clones ranged from 24% to less than 0.1%, and the difference in replication levels was as high as 100-fold. As expected, significant differences were observed in the recombination frequencies, which ranged from 0.5% to 47.5%. Furthermore, varying the relative amounts of parental RNA altered the dominant recombinant species produced, suggesting that template switching occurs frequently during the synthesis of genomic HDV RNA. Taken together, these data suggest that during the host RNA polymerase-driven RNA recombination of HDV, both inter- and intra-genotypic recombination events are important in shaping the genetic diversity of HDV.
Subject(s)
Hepatitis Delta Virus/genetics , Hepatitis Delta Virus/physiology , RNA, Viral/genetics , Recombination, Genetic , Virus Replication , Genetic Variation , Humans , Polymorphism, Restriction Fragment Length , Reverse Transcriptase Polymerase Chain Reaction , TransfectionABSTRACT
Trefoil factor 3 (TFF3), also called intestinal trefoil factor or Itf, is a 59 amino acid peptide found as a homodimer predominantly along the gastrointestinal tract and in serum. TFF3 expression is elevated during gastrointestinal adenoma progression and has been shown to promote mucosal wound healing. Here we show that in contrast to other trefoil factor family members, TFF1 and TFF2, TFF3 is highly expressed in mouse duodenum, jejunum and ileum and that its expression is regulated by food intake. Overexpression of TFF3 using a recombinant adeno-associated virus (AAV) vector, or daily administration of recombinant TFF3 protein in vivo improved glucose tolerance in a diet-induced obesity mouse model. Body weight, fasting insulin, triglyceride, cholesterol and leptin levels were not affected by TFF3 treatment. Induction of mucinous metaplasia was observed in mice with AAV-mediated TFF3 overexpression, however, no such adverse histological effect was seen after the administration of recombinant TFF3 protein. Altogether these results suggest that the therapeutic potential of targeting TFF3 to treat T2D may be limited.
Subject(s)
Blood Glucose/metabolism , Eating/genetics , Genetic Vectors/adverse effects , Metaplasia/genetics , Mucins/genetics , Obesity/genetics , Animals , Cholesterol/blood , Dependovirus/genetics , Diet, High-Fat , Duodenum/metabolism , Duodenum/pathology , Gene Expression , Gene Expression Regulation , Genetic Vectors/chemistry , Genetic Vectors/metabolism , Glucose Tolerance Test , Humans , Ileum/metabolism , Ileum/pathology , Insulin/blood , Jejunum/metabolism , Jejunum/pathology , Leptin/blood , Male , Metaplasia/etiology , Metaplasia/metabolism , Metaplasia/pathology , Mice , Mucins/administration & dosage , Mucins/metabolism , Obesity/etiology , Obesity/metabolism , Obesity/pathology , Recombinant Proteins/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Signal Transduction , Trefoil Factor-2 , Trefoil Factor-3 , Triglycerides/bloodABSTRACT
OBJECTIVE: Although the human genome encodes â¼ 20,000 protein-coding genes, only a very small fraction of these have been explored as potential targets for therapeutic development. The challenge of identifying and validating new protein targets has contributed to the significant reduction in the productivity of the pharmaceutical industry in the recent decade, highlighting the continued need to find new therapeutic targets. RESEARCH DESIGN AND METHODS: The traditional methods to discover new targets are expensive, low throughput and time consuming, usually taking years to validate or invalidate a target. To address these limitations, as a proof of concept, we explored the hydrodynamic tail vein (HTV) injection as a gene delivery method for direct in vivo phenotypic screening of novel secreted factor targets for Type II diabetes therapeutics. RESULTS: High levels and sustained expression of target proteins were observed in diabetic mouse models tested, allowing us to identify multiple novel hormones that may regulate glucose metabolism. CONCLUSIONS: These results suggest that HTV is a low-cost, high-throughput method for direct in vivo phenotypic drug screening in metabolic disorders and could be applicable to many other disease areas as well. This method if combined with other approaches such as human genetic studies could provide a significant value to future drug discovery.
Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/pharmacology , Proteome , Animals , Diabetes Mellitus, Experimental/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Drug Discovery/methods , Gene Transfer Techniques , Glucose/metabolism , High-Throughput Screening Assays/methods , Humans , Hydrodynamics , Injections, Intravenous , Male , Mice , Mice, Inbred C57BL , Phenotype , Tail/blood supplyABSTRACT
The discovery and optimization of a series of acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors based on a pyrimido[4,5-b][1,4]oxazine scaffold is described. The SAR of a moderately potent HTS hit was investigated resulting in the discovery of phenylcyclohexylacetic acid 1, which displayed good DGAT1 inhibitory activity, selectivity, and PK properties. During preclinical toxicity studies a metabolite of 1 was observed that was responsible for elevating the levels of liver enzymes ALT and AST. Subsequently, analogues were synthesized to preclude the formation of the toxic metabolite. This effort resulted in the discovery of spiroindane 42, which displayed significantly improved DGAT1 inhibition compared to 1. Spiroindane 42 was well tolerated in rodents in vivo, demonstrated efficacy in an oral triglyceride uptake study in mice, and had an acceptable safety profile in preclinical toxicity studies.